Sign In
Buy GMAB
$25.94
+0.330 (+1.29%)
At Close: Jun 23, 2026
Capital Increase in Genmab as a Result of Employee Warrant Exercise
03:12pm, Tuesday, 16'th Jun 2026
Company Announcement COPENHAGEN, Denmark; June 16, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 185 shares as a consequence of the exercise of employee warrants. The increase
Major Shareholder Announcement
12:04pm, Monday, 15'th Jun 2026
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 15, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Market
[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously
Media Release COPENHAGEN, Denmark; June 13, 2026 Results from the Phase 2 EPCORE ® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newl
Grant of Restricted Stock Units and Warrants to Employees in Genmab
01:17pm, Thursday, 11'th Jun 2026
Company Announcement COPENHAGEN, Denmark; June 11, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 15,894 restricted stock units and 15,494 warrants to
Media Release COPENHAGEN, Denmark; June 11, 2026 Findings from a post-hoc subgroup analysis of the Phase 3 EPCORE ® FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and l
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
04:35pm, Friday, 29'th May 2026
Company Announcement COPENHAGEN, Denmark; May 29, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, th
Media Release COPENHAGEN, Denmark; May 21, 2026 Twenty-three abstracts will highlight the versatility and strength of Genmab's portfolio and pipeline, including data from the comprehensive epcoritamab
Genmab A/S (GMAB) Q1 2026 Earnings Call Transcript
08:43am, Thursday, 14'th May 2026
Genmab A/S (GMAB) Q1 2026 Earnings Call Transcript
Capital Increase in Genmab as a Result of Employee Warrant Exercise
01:46pm, Tuesday, 12'th May 2026
Company Announcement COPENHAGEN, Denmark; May 12, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 2,346 shares as a consequence of the exercise of employee warrants. The increase
Genmab Announces Financial Results for the First Quarter of 2026
11:02am, Thursday, 07'th May 2026
May 7, 2026 Copenhagen, Denmark; Interim Report for the Three Months Ended March 31, 2026 Highlights Genmab revenue increased 25% compared to the first three months of 2025 , to $896 million FDA appro
Genmab A/S Share Capital Reduction
10:56am, Friday, 17'th Apr 2026
Company Announcement COPENHAGEN, Denmark; April 17, 2026 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S' Annual General Meeting on March 19, 2026, it was decided to reduce the Company's share capital wit
Major Shareholder Announcement
10:44am, Tuesday, 14'th Apr 2026
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Marke
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
06:23am, Tuesday, 14'th Apr 2026
Company Announcement Net sales of DARZALEX ® in the first quarter of 2026 totaled USD 3,964 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen
Media Release COPENHAGEN, Denmark; April 13, 2026 Phase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S ® ) and bevacizumab was tolerable, with no new safety signals in
